PE20030497A1 - Combinaciones de un inhibidor de pde 5 y otros agentes activos - Google Patents
Combinaciones de un inhibidor de pde 5 y otros agentes activosInfo
- Publication number
- PE20030497A1 PE20030497A1 PE2002000949A PE2002000949A PE20030497A1 PE 20030497 A1 PE20030497 A1 PE 20030497A1 PE 2002000949 A PE2002000949 A PE 2002000949A PE 2002000949 A PE2002000949 A PE 2002000949A PE 20030497 A1 PE20030497 A1 PE 20030497A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- alcoxy
- alkyl
- hydroxy
- server
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMBINACION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DE PDE 5 DE FORMULA I DONDE R1 ES H, ALQUILO OPCIONALMENTE SUSTITUIDA POR HIDROXI, ALCOXI, ALQUILTIO; R2 ES H, ALQUILO, HIDROXIALQUILO, ALQUILCARBONILOXIALQUILO, ALCOXIALQUILO, ALQUILTIOALQUILO, ENTRE OTROS; R3 ES H, ALQUILO OPCIONALMENTE SUSTITUIDA POR HIDROXI, ALCOXI ALQUILTIO; R4 ES H, ALQUILO; R5 ES QUINOLILO, ISOQUINOLILO, OXODIHIDROISOQUINOLILO OPCIONALMENTE FUSIONADO A UN GRUPO HETEROCICLO DE 5 MIEMBROS; R6 Y R7 SON H, ALQUILO OPCIONALMENTE SUSTITUIDO POR HIDROXI, ALCOXI; DE PREFERENCIA 3-ISOBUTIL-8-(6-METOXI-ISOQUINOLIN-4-ILMETIL)-1-3,7-DIHIDRO-PURIN-2,6-DIONA; UN AGENTE ACTIVO SELECCIONADO DE UN AGENTE ANTIDIABETICO TAL COMO INSULINA; INHIBIDORES DE HMGCOA REDUCTASA TAL COMO ATORVASTATINA, CERIVASTATINA, FLUVASTATINA, ROSUVASTATINA, ENTRE OTROS, UN AGENTE ANTIHIPERTENSIVO TAL COMO INHIBIDORES DE ACE, BLOQUEADORES ADRENERGICOS, DIURETICOS, ENTRE OTROS, INHIBIDOR DE LA REABSORCION DE SEROTONINA SSRI TAL COMO FLUVOXAMINA, FLUOXETINA, PAROXETINA, SERTRALINA, ENTRE OTROS. LA COMBINACION PUEDE SER UTIL PARA LA PREVENCION O TRATAMIENTO DE DISFUNCION SEXUAL, HIPERGLICEMIA, HIPERINSULINEMIA, HIPERLIPIDEMIA, DIABETES, HIPERTRIGLICERIDEMIA, OBESIDAD, RETINOPATIA DIABETICA, GLOMERULOESCLEROSIS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32548501P | 2001-09-27 | 2001-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20030497A1 true PE20030497A1 (es) | 2003-07-04 |
Family
ID=23268071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2002000949A PE20030497A1 (es) | 2001-09-27 | 2002-09-26 | Combinaciones de un inhibidor de pde 5 y otros agentes activos |
Country Status (12)
Country | Link |
---|---|
US (1) | US20030114469A1 (es) |
EP (1) | EP1432423A2 (es) |
JP (1) | JP2005504113A (es) |
CN (1) | CN1694707A (es) |
AR (1) | AR036584A1 (es) |
AU (1) | AU2002338806A1 (es) |
BR (1) | BR0212852A (es) |
CA (1) | CA2458343A1 (es) |
MY (1) | MY134639A (es) |
PE (1) | PE20030497A1 (es) |
TW (1) | TW200412970A (es) |
WO (1) | WO2003028730A2 (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
CA2516250A1 (en) | 2003-02-19 | 2004-09-02 | Endacea, Inc. | A1 adenosine receptor antagonists |
MXPA05009242A (es) * | 2003-03-17 | 2006-04-18 | Pfizer Prod Inc | Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5. |
WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
JP2006528229A (ja) * | 2003-05-22 | 2006-12-14 | アルタナ ファルマ アクチエンゲゼルシャフト | Pde4阻害剤及びpde5阻害剤を含有する組成物 |
WO2005009343A2 (en) * | 2003-06-06 | 2005-02-03 | Endacea, Inc. | A1 adenosine receptor antogonists |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
WO2005041972A1 (en) * | 2003-10-31 | 2005-05-12 | Pfizer Products Inc. | Phosphodiesterase 9 inhibition as treatment for obesity-related conditions |
TW200605893A (en) * | 2004-02-12 | 2006-02-16 | Novartis Ag | Use of organic compounds |
EP1737465A4 (en) * | 2004-04-19 | 2007-10-03 | Univ Loma Linda | COMPOSITION AND METHOD FOR REDUCING RENAL ISCHEMIC DAMAGE |
CA2564517A1 (en) * | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 1-aryl-4-substituted isoquinolines |
CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
PT1814527E (pt) * | 2004-11-05 | 2014-01-16 | Boehringer Ingelheim Int | Comprimido de bicamada compreendendo telmisartan e amlodipina |
WO2006132091A1 (ja) * | 2005-06-08 | 2006-12-14 | Kowa Company, Ltd. | 新規なトリグリセリド低下剤 |
EP1906934A4 (en) * | 2005-07-14 | 2012-03-07 | Franco Folli | DAILY DOSAGE SCHEME FOR THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME AND POLYKYSTIC OVAIRE SYNDROME |
JP5330825B2 (ja) | 2006-03-29 | 2013-10-30 | 興和株式会社 | トリグリセリド低下剤及び高インスリン血症改善剤 |
ATE513831T1 (de) * | 2006-04-21 | 2011-07-15 | Pfizer Prod Inc | Pyridinä3,4-büpyrazinone |
ME01648B (me) | 2006-07-05 | 2014-09-20 | Nycomed Gmbh | Kombinacija inhibitora hmg-coa reduktaze rosuvastatina sa inhibitorom fosfodiesteraze 4,kao što je roflumilast, roflumilast-n-oksid za liječenje inflamatornih plućnih oboljenja |
US8841300B2 (en) | 2006-10-02 | 2014-09-23 | Jerry M. Held | Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor |
WO2008144061A2 (en) * | 2007-05-18 | 2008-11-27 | Vivus, Inc. | Novel combinations comprising a phosphodiesterase-5 inhibitor and their use |
EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
CN103476757A (zh) * | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
HUE032613T2 (en) | 2012-06-04 | 2017-10-30 | Diamedica Therapeutics Inc | Human tissue kallikrein 1 is glycosylated isoforms |
WO2014071044A1 (en) * | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
EP3592377A4 (en) | 2017-03-09 | 2021-02-17 | Diamedica Inc. | DOSAGE FORMS OF TISSUE KALLIKREIN 1 |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1037616B1 (en) * | 1997-12-16 | 2006-03-01 | Pfizer Products Inc. | COMBINATION OF ALPHA-1-ADRENERGIC ANTAGONISTS AND A CGMP PDEv INHIBITOR FOR THE TREATMENT OF IMPOTENCE |
DE19844162A1 (de) * | 1998-09-25 | 2000-03-30 | Udo Dunzendorfer | Medikamentenkombinationen zur Therapie der erektilen Dysfunktion |
US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
HUP0300725A3 (en) * | 2000-08-11 | 2005-11-28 | Pfizer | Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
US6683080B2 (en) * | 2001-02-02 | 2004-01-27 | Pfizer Inc. | Treatment of diabetes mellitus |
-
2002
- 2002-08-28 US US10/231,427 patent/US20030114469A1/en not_active Abandoned
- 2002-09-25 AR ARP020103611A patent/AR036584A1/es unknown
- 2002-09-25 TW TW093102932A patent/TW200412970A/zh unknown
- 2002-09-26 BR BR0212852-7A patent/BR0212852A/pt not_active IP Right Cessation
- 2002-09-26 EP EP02777227A patent/EP1432423A2/en not_active Withdrawn
- 2002-09-26 AU AU2002338806A patent/AU2002338806A1/en not_active Abandoned
- 2002-09-26 PE PE2002000949A patent/PE20030497A1/es not_active Application Discontinuation
- 2002-09-26 CA CA002458343A patent/CA2458343A1/en not_active Abandoned
- 2002-09-26 WO PCT/EP2002/010826 patent/WO2003028730A2/en active Application Filing
- 2002-09-26 JP JP2003532062A patent/JP2005504113A/ja active Pending
- 2002-09-26 CN CNA028190467A patent/CN1694707A/zh active Pending
- 2002-09-27 MY MYPI20023630A patent/MY134639A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR036584A1 (es) | 2004-09-15 |
US20030114469A1 (en) | 2003-06-19 |
WO2003028730A2 (en) | 2003-04-10 |
TW200412970A (en) | 2004-08-01 |
BR0212852A (pt) | 2004-10-13 |
WO2003028730A3 (en) | 2003-09-04 |
EP1432423A2 (en) | 2004-06-30 |
JP2005504113A (ja) | 2005-02-10 |
CA2458343A1 (en) | 2003-04-10 |
CN1694707A (zh) | 2005-11-09 |
AU2002338806A1 (en) | 2003-04-14 |
MY134639A (en) | 2007-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20030497A1 (es) | Combinaciones de un inhibidor de pde 5 y otros agentes activos | |
PE20020771A1 (es) | Pirrolidina fusionada con ciclopropilo como inhibidores de dipeptidil peptidas iv | |
ATE370141T1 (de) | Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase | |
HUP0400365A2 (hu) | 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények | |
IL149150A0 (en) | 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors | |
PE20001317A1 (es) | N-(glicilo sustituido)-2-cianopirrolidinas como inhibidores de dpp-iv | |
PE20060777A1 (es) | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas | |
BRPI0507495A (pt) | composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5 | |
PE20010684A1 (es) | Inhibidores de la reincorporacion de norepinefrina altamente selectivos y metodos para usarlos | |
AR054799A1 (es) | Derivados de oxindol | |
DE60315336D1 (de) | Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv) | |
PE20000427A1 (es) | Nuevas dihidropirimidinas | |
PE20060525A1 (es) | Compuestos heterociclicos como inhibidores de cetp | |
ATE381539T1 (de) | Dipeptidylpeptidase-hemmer zur behandlung von diabetes | |
PE58699A1 (es) | Derivados de acido arilsulfonil hidroxamico | |
PE20000428A1 (es) | Nuevas dihidropirimidinas 2 heterociclicamente sustituidas | |
PE20010126A1 (es) | Pirrolotriazinas como inhibidores de cinasas | |
BR0315796A (pt) | Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero | |
PT1088824E (pt) | Pirrolil-amidas biciclicas como inibidores de glicogenio-fosforilase | |
PE20020573A1 (es) | Derivados glucopiranosiloxibencilbenceno, composiciones farmaceuticas que los comprenden e intermedios de los mismos | |
PE20020722A1 (es) | Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano | |
DK0778834T3 (da) | Bicykliske, heterocykliske diarylforbindelser som inhibitorer af cyclooxygenase-2 | |
CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
RU2010126056A (ru) | Органические соединения | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |